BeiGene

Results from a phase 1b open-label, multi-center, non-randomized, study investigating the safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant (R/R) unresectable or metastatic melanoma.